Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%. Janssen is looking to broaden the use of its multiple myeloma blockbuster Darzalex, this time combining it with Celgene’s Revlimid ... Those patients were directly compared to a group taking

NICE partially clears Darzalex combo in blood cancer

Notably, 29% of those in one trial arm used Celgene’s Revlimid as their first-line treatment; where as only 12% in the other group used Darzalex. ... Clinical experts stated that there was no evidence to suggest that Revlimid modifies the effect of

BMS trades blows with investor on Celgene deal merits

The activist investors claim that BMS is buying a company with a massive patent cliff – principally blood cancer blockbuster Revlimid (lenalidomide) – which they say will requite Celgene to replace 60% of

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

It also met the secondary endpoint of overall survival, with only 16 death events reported in the Revlimid combo group versus 26 death events in the comparator arm. ... It's one of five new drugs that Celgene aims to launch through 2020, and the company

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]